Please assess the completion status of the following clinical trial:

Trial Title: Artemether/Lumefantrine and Vivax Malaria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with vivax malaria~Exclusion Criteria:~* severe malaria~* pregnancy

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- artemether-lumefantrine (Type: EXPERIMENTAL): tablets (containing 20mg artemether and 120 mg lumefantrine) for three days

Based on this trial design, predict the completion outcome and termination type (if applicable).